Curated News
By: NewsRamp Editorial Staff
May 08, 2025
GeoVax Labs Showcases Robust COVID-19 and Mpox Immunogenicity in Clinical Study
TLDR
- GEO-CM04S1 offers broad, durable immunity against COVID-19 and Mpox, providing a competitive advantage in vaccine development.
- GEO-CM04S1, a next-gen multi-antigen COVID-19 vaccine, stimulates strong immunity via synthetic MVA vector platform expressing S and N antigens.
- GEO-CM04S1's cross-protective potential against Mpox and variants contributes to a safer world, especially in endemic regions like Africa.
- COH04S1-vaccinated individuals' sera protect mice from lung infection by Mpox virus, showcasing a fascinating aspect of vaccine efficacy.
Impact - Why it Matters
This news matters as it highlights the potential of GEO-CM04S1 to provide dual protection against COVID-19 and Mpox, especially in immunocompromised individuals. The study's findings could lead to the development of more effective vaccines offering broader and durable immunity against current and emerging variants.
Summary
GeoVax Labs, Inc. presented clinical data for its next-generation multi-antigen COVID-19 vaccine GEO-CM04S1 at IMMUNOLOGY2025™. The study demonstrated robust immune responses against SARS-CoV-2 and cross-protective potential against Mpox in blood cancer patients and healthy adults.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, GeoVax Labs Showcases Robust COVID-19 and Mpox Immunogenicity in Clinical Study
